The Impact of the Pharmaceutical Care Management Model of Hepatitis C Medications on the Cost at Health Insurance Level

A systematic review on the impact of pharmacist‐provided services on patients’ health outcomes in Arab countries

“…47,49 One retrospective cohort study by Elewa et al also found that a high percentage of patients in the intervention group experienced a therapeutic INR compared to the control group. 48 The impact of pharmacist-provided care was also recognized in improving clinical outcomes in studies that focused on patients with dyslipidaemia, 55 heart failure, 56 polycystic ovary syndrome, 57 anaemia, 60 metabolic syndrome 63 and hepatitis C. 64 Moreover, this positive impact was also demonstrated in studies that did not include patients with specific medical conditions, but focused on patients with polypharmacy or multiple chronic conditions. 58,61 Other studies reported a positive effect of pharmacist care on hospitalization, 46,54,58,65 sickness days 46 and emergency department visits.…”

“…49,54,64,69,70 Ten studies reported multiple outcomes. 39,43,46,49,52,54,56,62,64,69 The majority of the included studies were RCTs (n = 26), conducted in Jordan (n = 20) and in hospital settings (n = 26) (Table 1). Most of the studies involved patients with specific medical conditions, including diabetes (n = 8), [36][37][38][39][40][41][42][43] asthma (n = 4), [44][45][46]69 hypertension (n = 4), [50][51][52][53] receiving warfarin therapy (n = 4) [47][48][49]71 and other medical conditions (n = 9).…”

“…Most of the studies involved patients with specific medical conditions, including diabetes (n = 8), [36][37][38][39][40][41][42][43] asthma (n = 4), [44][45][46]69 hypertension (n = 4), [50][51][52][53] receiving warfarin therapy (n = 4) [47][48][49]71 and other medical conditions (n = 9). [55][56][57]59,60,[62][63][64]68 The remaining studies (n = 6) 58,61,[65][66][67]70 included generic characteristics such as patients for discharge 58 or patients receiving polypharmacy. 61 The pharmacist's intervention involved mainly one or more of the following, MTM (n = 32), [60][61][62][63][64][66][67][68][69] pharmacist-led counselling or education (n = 29) [36][37...…”

“…[55][56][57]59,60,[62][63][64]68 The remaining studies (n = 6) 58,61,[65][66][67]70 included generic characteristics such as patients for discharge 58 or patients receiving polypharmacy. 61 The pharmacist's intervention involved mainly one or more of the following, MTM (n = 32), [60][61][62][63][64][66][67][68][69] pharmacist-led counselling or education (n = 29) [36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][55][56][57]60,62,63,[65]…”

“…61 The pharmacist's intervention involved mainly one or more of the following, MTM (n = 32), [60][61][62][63][64][66][67][68][69] pharmacist-led counselling or education (n = 29) [36][37][38][39][40][41][42][43][44][45][46][47][48][49][50][51][52][53][55][56][57]60,62,63,[65][66][67][68][69] and medication recommendations to physicians (n = 12). 36,39,40,51,[54][55][56]58,61,63,64,70 3.3 | Impact of pharmacist's intervention…”